{"title":"A note on stratification errors in the analysis of clinical trials","authors":"Neal Thomas","doi":"10.1080/19466315.2023.2241415","DOIUrl":null,"url":null,"abstract":"Stratification in both the design and analysis of randomized clinical trials is common. Despite features in automated randomization systems to re-confirm the stratifying variables, incorrect values of these variables may be entered. These errors are often detected during subsequent data collection and verification. Questions remain about whether to use the mis-reported initial stratification or the corrected values in subsequent analyses. It is shown that the likelihood function resulting from the design of randomized clinical trials supports the use of the corrected values. New definitions are proposed that characterize misclassification errors as `ignorable' and `non-ignorable'. Ignorable errors may depend on the correct strata and any other modeled baseline covariates, but they are otherwise unrelated to potential treatment outcomes. Data management review suggests most misclassification errors are arbitrarily produced by distracted investigators, so they are ignorable or at most weakly dependent on measured and unmeasured baseline covariates. Ignorable misclassification errors may produce a small increase in standard errors, but other properties of the planned analyses are unchanged (e.g., unbiasedness, confidence interval coverage). It is shown that unbiased linear estimation in the absence of misclassification errors remains unbiased when there are non-ignorable misclassification errors, and the corresponding confidence intervals based on the corrected strata values are conservative.","PeriodicalId":51280,"journal":{"name":"Statistics in Biopharmaceutical Research","volume":" ","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2023-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Statistics in Biopharmaceutical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/19466315.2023.2241415","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MATHEMATICAL & COMPUTATIONAL BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Stratification in both the design and analysis of randomized clinical trials is common. Despite features in automated randomization systems to re-confirm the stratifying variables, incorrect values of these variables may be entered. These errors are often detected during subsequent data collection and verification. Questions remain about whether to use the mis-reported initial stratification or the corrected values in subsequent analyses. It is shown that the likelihood function resulting from the design of randomized clinical trials supports the use of the corrected values. New definitions are proposed that characterize misclassification errors as `ignorable' and `non-ignorable'. Ignorable errors may depend on the correct strata and any other modeled baseline covariates, but they are otherwise unrelated to potential treatment outcomes. Data management review suggests most misclassification errors are arbitrarily produced by distracted investigators, so they are ignorable or at most weakly dependent on measured and unmeasured baseline covariates. Ignorable misclassification errors may produce a small increase in standard errors, but other properties of the planned analyses are unchanged (e.g., unbiasedness, confidence interval coverage). It is shown that unbiased linear estimation in the absence of misclassification errors remains unbiased when there are non-ignorable misclassification errors, and the corresponding confidence intervals based on the corrected strata values are conservative.
期刊介绍:
Statistics in Biopharmaceutical Research ( SBR), publishes articles that focus on the needs of researchers and applied statisticians in biopharmaceutical industries; academic biostatisticians from schools of medicine, veterinary medicine, public health, and pharmacy; statisticians and quantitative analysts working in regulatory agencies (e.g., U.S. Food and Drug Administration and its counterpart in other countries); statisticians with an interest in adopting methodology presented in this journal to their own fields; and nonstatisticians with an interest in applying statistical methods to biopharmaceutical problems.
Statistics in Biopharmaceutical Research accepts papers that discuss appropriate statistical methodology and information regarding the use of statistics in all phases of research, development, and practice in the pharmaceutical, biopharmaceutical, device, and diagnostics industries. Articles should focus on the development of novel statistical methods, novel applications of current methods, or the innovative application of statistical principles that can be used by statistical practitioners in these disciplines. Areas of application may include statistical methods for drug discovery, including papers that address issues of multiplicity, sequential trials, adaptive designs, etc.; preclinical and clinical studies; genomics and proteomics; bioassay; biomarkers and surrogate markers; models and analyses of drug history, including pharmacoeconomics, product life cycle, detection of adverse events in clinical studies, and postmarketing risk assessment; regulatory guidelines, including issues of standardization of terminology (e.g., CDISC), tolerance and specification limits related to pharmaceutical practice, and novel methods of drug approval; and detection of adverse events in clinical and toxicological studies. Tutorial articles also are welcome. Articles should include demonstrable evidence of the usefulness of this methodology (presumably by means of an application).
The Editorial Board of SBR intends to ensure that the journal continually provides important, useful, and timely information. To accomplish this, the board strives to attract outstanding articles by seeing that each submission receives a careful, thorough, and prompt review.
Authors can choose to publish gold open access in this journal.